Intratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses
Jiang X, Fedorova O, Linehan M, Dong H, Pyle A, Iwasaki A. Intratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses. The Journal Of Immunology 2019, 202: 194.28-194.28. DOI: 10.4049/jimmunol.202.supp.194.28.Peer-Reviewed Original ResearchAnti-tumor efficacyRobust anti-tumor immune responseAnti-tumor immune responseTumor microenvironmentNucleic acid-sensing pathwaysT-cell depletionTumor-infiltrating lymphocytesCytosolic nucleic acid-sensing pathwaysB16 melanoma growthVivo anti-tumor efficacyPromising therapeutic agentLong-term survivalRemarkable antitumor effectImmunogenic tumorsInnate cellsCell depletionCancer immunotherapyMouse survivalImmune responseTumor volumeCombination treatmentIntratumoral deliveryAntitumor effectsMelanoma growthTumor subtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply